A Study to Determine the Effects of MK0557 in Obese Subjects

This study has been completed.

Sponsored by:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00533598

Purpose

The purpose of this study is to assess the effects of MK0557 on body weight in obese subjects.

Condition	Intervention	Phase
Obesity	Drug: MK0557	Phase II

MedlinePlus related topics: Obesity

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Further study details as provided by Merck:

Study Start Date:	December 2003
Study Completion Date:	December 2003

Eligibility

Criteria

Inclusion Criteria:

Men and women between 21 and 65 years of age, willing to avoid all prescription and nonprescription medicine to alter body weight for entire study

Exclusion Criteria:

You are or plan to become pregnant
You have smoked or used nicotine within 6 months of the study
History of abusing alcohol and/or drugs
History of a stroke, you have diabetes mellitus, you are taking medication for high blood pressure, you have had recent surgery, you have been involved in another study within 3 months of study, use of cholesterol or anti-seizure medication during the study
Have participated in a weight loss program 3 months before the study or during the course of the study

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00533598

Sponsors and Collaborators

Merck

Investigators

Study Director:

Medical Monitor

Merck

More Information

Study ID Numbers:	2007_613
Study First Received:	September 19, 2007
Last Updated:	September 20, 2007
ClinicalTrials.gov Identifier:	NCT00533598
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Body Weight
Signs and Symptoms
Obesity

Nutrition Disorders
Overweight
Overnutrition

ClinicalTrials.gov processed this record on January 16, 2009